As previously reported, Oppenheimer analyst Esther Rajavelu downgraded Vanda Pharmaceuticals to Perform from Outperform saying that with the tasimelteon Smith-Magenis Syndrome trial meeting one of the two primary endpoints, the stock fairly reflects the inherent risk/reward at current trading levels. The analyst will await on the sidelines the publication of the results and an update on the regulatory strategy post the pre-NDA meeting.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.